Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life

NCT06995430 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06995430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06995430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
July 7, 2025
Completion date
December 15, 2025
Enrollment
312 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

meningitis